Search - tctmd.com

Displaying 1 - 20 of 1071

Sort: Relevancy | Date

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

February 02, 2026

Periprocedural MI Signals Worse Outcomes in Stented NSTE ACS Patients: MATRIX

News Daily News

Periprocedural MI Signals Worse Outcomes in Stented NSTE ACS Patients: MATRIX

Michael O'Riordan

January 15, 2026

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

News Daily News

Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure

Michael O'Riordan

December 30, 2025

Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News

News Daily News

Year in Review: Reimbursement, Funding Cuts Mark Top Policy & Practice News

Yael L. Maxwell

December 26, 2025

Remission From Prediabetes Halves CV Risk: Registry Data

News Daily News

Remission From Prediabetes Halves CV Risk: Registry Data

Yael L. Maxwell

December 19, 2025

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

TAVI Patients Seem to Pay No Penalty for Obstructive CAD

News Daily News

TAVI Patients Seem to Pay No Penalty for Obstructive CAD

Yael L. Maxwell

December 09, 2025

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

News Daily News

Revascularization Decisions in the Elderly Require a Holistic Approach: AHA

November 24, 2025

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

News Daily News

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

November 21, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

TCTMD’s Top 10 Most Popular Stories for October 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2025

November 03, 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

News Conference News TCT 2025

LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI

October 27, 2025

Presentation TCT 2025

TCT 1032: A Randomized Pilot Trial Comparing Combined Catheter-Interventional Treatment versus Standard of Care in Intermediate High-Risk Pulmonary Embolism

Presenter: Karl Fengler

October 26, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

SAVR Bests TAVI for 5-Year Survival in Combined RCT, Observational Data

News Conference News EACTS 2025

SAVR Bests TAVI for 5-Year Survival in Combined RCT, Observational Data

Yael L. Maxwell

October 10, 2025

ESTREL: Levodopa Doesn’t Boost Rehab Benefits After Acute Stroke

News Daily News

ESTREL: Levodopa Doesn’t Boost Rehab Benefits After Acute Stroke

September 25, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.